Go Pro
→ U.S. energy boom: The next big winner? (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
$0.22
$0.22
$0.11
▼
$0.89
$11.42M0.5127,352 shsN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.37
-6.2%		$1.32
$0.83
▼
$2.46
$24.34M1.575,402 shs84,784 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+0.69%+19.67%+23.73%-7.01%+55.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
$0.22
$0.22
$0.11
▼
$0.89
$11.42M0.5127,352 shsN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.37
-6.2%		$1.32
$0.83
▼
$2.46
$24.34M1.575,402 shs84,784 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+0.69%+19.67%+23.73%-7.01%+55.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
0.00
N/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.00629.93% Upside

Current Analyst Ratings Breakdown

Latest ATBPF and MRKR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/21/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/24/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/AN/AN/AN/A$0.58 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M6.43N/AN/A$0.73 per share1.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
-$14.73M-$0.25N/AN/AN/AN/A-56.48%-29.07%N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.41N/AN/AN/A-343.03%-56.96%-47.82%11/12/2026 (Estimated)

Latest ATBPF and MRKR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.25-$0.09+$0.16-$0.09$0.68 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/A
10.06
10.06
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
6.03
6.03

Institutional Ownership

CompanyInstitutional Ownership
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%

Insider Ownership

CompanyInsider Ownership
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
9.00%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
5.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
1152.98 million48.24 millionNot Optionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable

Recent News About These Companies

Q3 EPS Forecast for Marker Therapeutics Boosted by Analyst
August 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30979129
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR) and CSPC Pharmaceutical Group (OtherCHJTF)
August 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRKR/pressreleases/3969567/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-and-cspc-pharmaceutical-group-otherchjtf/
MRKR Q3 EPS Estimate Increased by Brookline Capital Markets
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973378
Brokers Issue Forecasts for MRKR FY2028 Earnings
August 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971452
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
June 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2943342/zacks-industry-outlook-indivior-aurinia-ironwood-altimmune-and-marker?cid=cs-stocknewsapi-ft-press_releases-2943342
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
June 25, 2026  |  zacks.comhttps://www.zacks.com/commentary/2942605/5-small-drug-stocks-to-invest-in-amid-a-biotech-comeback?cid=cs-stocknewsapi-ft-industry_outlook-2942605
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2924277/marker-therapeutics-mrkr-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2924277
Marker Therapeutics Sets Date for 2026 Annual Meeting
May 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRKR-Q/pressreleases/141978/marker-therapeutics-sets-date-for-2026-annual-meeting/
Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02
April 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/marker-therapeutics-mrkr-price-target-decreased-by-12-83-to-8-02/ar-AA20ulsd
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
March 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2886298/marker-therapeutics-inc-mrkr-reports-q4-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2886298
Marker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-Oncology
March 18, 2026  |  quiverquant.comQ
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258655/0/en/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results.html
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/18/3240173/0/en/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference.html
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
January 26, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/good-morning-america-features-baylor-college-of-medicine-pancreatic-cancer-study-utilizing-marker-therapeutics-mar-t-cell-technology-1035745259
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Pasithea Therapeutics Corp (KTTA) and TransMedics Group (TMDX)
January 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/37179524/analysts-offer-insights-on-healthcare-companies-marker-therapeutics-mrkr-pasithea-therapeutics-corp-ktta-and-transmedics-group-tmdx/
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
January 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2820215/mrkr-stock-up-nearly-114-in-3-months-here-s-what-you-need-to-know?cid=cs-stocknewsapi-ft-analyst_blog|price_surge_/_plunge-2820215
Marker Therapeutics, Inc. Common Stock (MRKR)
January 9, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/mrkr/insider-activity
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
January 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2813452/marker-therapeutics-inc-mrkr-now-trades-above-golden-cross-time-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|golden_crossover-2813452
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
January 7, 2026  |  zacks.comhttps://www.zacks.com/commentary/2813120/5-small-drug-stocks-to-buy-as-industry-recovery-picks-up?cid=cs-stocknewsapi-ft-industry_outlook-2813120
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
January 5, 2026  |  msn.comhttps://www.msn.com/en-us/science/biochemistry/marker-therapeutics-announces-publication-on-mar-t-cells-in-pancreatic-cancer/ar-AA1TC4mx

New MarketBeat Followers Over Time

Media Sentiment Over Time

Antibe Therapeutics stock logo

Antibe Therapeutics OTCMKTS:ATBPF

$0.22 0.00 (0.00%)
As of 08/26/2026

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.37 -0.09 (-6.16%)
As of 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas